1 January 17, 2008 Test Article Accountability. 2 January 17, 2008 Investigator Responsibilities 21 CFR 312.60-62  Maintain control of drug under investigation.

Slides:



Advertisements
Similar presentations
Common/shared responsibilities between jobs.
Advertisements

Essential Documentation GCP Training Seminar 12th October 2011
Maintenance, Management and Monitoring of Investigational Supply
Tips to a Successful Monitoring Visit
GCP for Investigators Tina Lidén Mascher, Kvalitetsregister, forskning och industrisamarbeten.
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.
Good Clinical Practices Regulatory Guidelines for the Conduct of Clinical research Introduction to Research Pharmacy Services Javier Palacios, R.Ph. Sponsored.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Andrew Schoch Pharmacy Intern Northeastern University Class of 2010
Investigational Pharmacy Issues Debbie Mundie, RPH Aka: The Drug “Nazi” “She should be in Law Enforcement” “She’s nice, but PICKY” McGuire VAMC Richmond.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Jennifer McCormick MA, CRC Karla Lichter RN CCRC.
Overview of Good Clinical Practices (GCPs)
Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.
Good Laboratory Practices (GLPs)
Monitoring and Special Considerations for Multi-Center Trials
Merrell Lim, Pharm.D. Investigational Drug Services Pharmacist
“So You Think You Know GCP …” Session S794 Jill Matzat, RN, BSN, CCRA, CCRT President, Medical Research Management & CRA Solutions, Inc. Paul Below, CCRA,
Yesterday, today, and tomorrow
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
Investigational New Drug Application (IND)
IMP management at site Dmitry Semenyuta. 2 TOP 5 FDA inspections finding Center of Drug Evaluation and Research (CDER) Failure to follow the.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance August 22, 2003.
Pharmaceutical Services Guidance Training CFR § , (a)(b)(1) F425.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
Study Closure Process Entropy is not a method Rachel Sheppard Regulatory Director, OCRSS.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
IP Accountability in Outpatient Clinical Trials
Pharmacy & The IRB Linda Sailor, BS, PharmD Rania Sadaka, BS, PharmD May 2015.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Pharmacist Training Revised September 2010
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
GCP (GOOD CLINICAL PRACTISE)
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Responsibilities of Sponsor, Investigator and Monitor
IP Accountability in Outpatient Clinical Trials Jessica Rinaldi, CCRP Farber Institute for Neurosciences.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Supervisory Responsibilities of Clinical Investigators
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
Inventory Management Chapter 13.
Quick Regulatory Guide
Facilitate Contract and Budget Negotiations
Responsibilities of Sponsor, Investigator and Monitor
Clinical Resources: LLUMC Investigational Drug Service
Catherine Gregor, MBA, CCRC, CCRP CRC Workshop August 1, 2014
Elements of an Organized Regulatory Binder
Basics of Building and Understanding Data Collection Forms
Audit Pharmacy Review Rosalyn D. Williams
Controlled Substances
Principles and Methods of Drug Administration
Controlled Substances
INTRODUCTION: Medications not being given must be safely stored
Investigational Pharmacy Service at BMC
OSU Controlled Substances Training Module for Researchers
Good clinical practice
Presentation transcript:

1 January 17, 2008 Test Article Accountability

2 January 17, 2008 Investigator Responsibilities 21 CFR  Maintain control of drug under investigation  Administer drug only to those subjects under investigator’s personal supervision or under supervision of sub investigator responsible to investigator  Supply drug only to those authorized to receive it Investigational Drug Service (IDS) for inpatient studies vs. staff  Security Controlled substance —Secure, locked, substantially constructed enclosure enclosure —Limited access

3 January 17, 2008 Investigator Responsibilities Additional ICH Requirements ICH GCP (E-6): 4.6, 4.7  Investigator Instruct subjects on using, handling, storing, and returning the investigational product(s) Check periodically that subject is in compliance with drug instructions Break blind only per protocol Promptly notify sponsor when blind is broken

4 January 17, 2008 Complete Medication Order   Name and History Number   Name of the medication   Dose with units of measure   Administration route   Time and frequency of administration   Titrated orders must be defined with desired effect   “Range orders” (e.g. 1-2 tabs or mg) eliminated wherever possible

5 January 17, 2008 Unsafe/Unauthorized Abbreviations Do Not UseInstead Use: μmcg or microgram Uunit 2.0 mg2 mg.25 mg0.25 mg MSO4 or MSmorphine MgSO4magnesium sulfate

6 January 17, 2008 Accountability Records General Information  Investigator’s name  Test article identification  Dispensing unit (e.g., vials, tablets, etc.)  Lot or batch number, if available  Protocol number  Number of units received  Investigator’s signature and date (end of study) Note: Product Label should state “Caution: New Drug-Limited by Federal (or United States Law) to investigational us

7 January 17, 2008 Accountability Records Dispensing/Administration Information  Initials/identifier of subject  Label code/identifier of test article  Date test article was dispensed  Quantity dispensed per container  Initials of study personnel dispensing the test article

8 January 17, 2008 Accountability Records Return Information  Date test article or container was returned by subject  Quantity of test article returned by subject  Comments, discrepancies and/or follow-up  Initials of study personnel receiving returned test article returned test article

9 January 17, 2008 Is The Subject Compliant?  Is there documentation of subject education?  Disposition and return discrepancies What is the compliance level? Packaging error? The right dose! At the right time! At the right time! The right way! The right way!

10 January 17, 2008 Is The Subject Compliant?  Other compliance issues Unused test article not returned Inadequate diary documentation Failure to maintain a consistent medication schedule Premature discontinuing of medication Failure to follow other protocol requirements related to medication (e.g. diet, disallowed medications)

11 January 17, 2008 Storage and Maintenance  Per protocol and federal/state laws  Keep storage areas clean, orderly, organized  Maintenance requirements per protocol Temperature logs —Room temperature —Refrigerator/Freezer —What is the back up plan if power fails?  Supplies sufficient?

12 January 17, 2008 Do the Numbers Add Up? Received from the Sponsor Lost, destroyed, returned to sponsor Administered/Dispensed Amount returned by subjects Minus Plus Balance on Hand

13 January 17, 2008 Accountability Check Track the Trail Dispensing/ Accountability Log CRF Source Diaries

14 January 17, 2008 Devices-What’s Different  Documentation of each subject’s use of the device  Calibration Calibration performed at intervals and according to directions specified in protocol Calibration records maintained  Temperature Log, if applicable  Repair and maintenance records maintained  Stored to maintain sterile packaging, if applicable

15 January 17, 2008 Randomization and Blinding  If applicable, randomization and blinding materials are kept intact  Unblinding Is it necessary to unblind? Was appropriate procedure followed and sponsor notified? —Documentation complete and accurate

16 January 17, 2008 Additional Information Site should follow all local regulations for accountability and storage of controlled substances Sponsor permission to destroy test article on site must be in writing

17 January 17, 2008 Investigational Drug Service (IDS)  Must use for inpatient research studies, outpatient optional currently  Handles drugs and biologics (not devices)  Keeps records of receipt, disposition to and return from site and return of drug to sponsor. Site must keep subject accountability records  Contact when considering/planning study  Investigator IND studies –will work with compounding pharmacy, provide packaging and labeling

18 January 17, 2008 Other Pharmacies Involved in Research at Duke   Investigational Cancer Service/“Oncology IDS”   HIV / AIDS Clinical Trials –Infectious Disease Clinic 2J   CHC Clinic Pharmacy –Outpatient Pediatric Studies

19 January 17, 2008 FACILITIES   Secured-Controlled-Monitored Location   Duke South, Room 0101-B, Yellow Zone   Facilities (monitored and alarmed)   800 square feet office/storage space   Class I and II LF Hoods   Biologic isolation chamber   Service Hours   On-site staff from 8 am to 4:30 pm M –F   24/7 On –call

20 January 17, 2008 IDS –IRB Relationship   Membership on IRB’s   Informational support to staff and chairs   Develop protocol preparation checklists: Drug nomenclature standards for consent forms Safe medication practices Eliminate unsafe abbreviations Pharmacy review for inpatient studies

21 January 17, 2008 What IDS Can Do For You   Consolidate activities and skills   Design Implementation Closeout   Integrate research into patient care activities   Comply with laws and standards   Coordinate production & packaging function   Educate staff on specifics of research

22 January 17, 2008 IDS Operations   Protocol Specific Services   Online pharmacy procedures   Online drug data sheets   Randomization, storage/security, accountability, blinding, preparation/compounding, patient counseling, staff education   Audits (FDA, CRO, Sponsor)   Records management

23 January 17, 2008 IDS Features and Benefits   IDS can benefit your study experience by: Reducing overall costs Assuring regulatory compliance Assuring inventory control Reducing unnecessary sponsor demands Eliminating risk due to unsafe medication practices Randomization and non-distribution services Assuring safe forms and label design Help develop education plans for clinical staff providing care, and more…

24 January 17, 2008 How to contact IDS   Room 0101-B, South Hospital, Yellow Zone   Phone: (919)   Fax: (919)   Pagers  